Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) - in Atrial Fibrillation

Trial Profile

Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) - in Atrial Fibrillation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs Edoxaban (Primary) ; Vitamin K antagonists
  • Indications Atrial fibrillation
  • Focus Adverse reactions
  • Acronyms ENVISAGE-TAVI AF
  • Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
  • Most Recent Events

    • 29 Aug 2018 Trial design published in the American Heart Journal.
    • 02 Nov 2017 Trial design presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 08 May 2017 According to a Daiichi Sankyo Company media release, first patients has been enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top